Patients with PAD were more likely to receive a statin (86% vs. 58%, p = 0.001), angiotensin-converting enzyme inhibitors (ACE-Is) or angiotensin II receptor blockers (ARBs) (63% vs. 35%, p = 0.001), and aspirin (64% vs. 47%, p = 0.019) compared to patients without PAD. Here, ACE is linked to peripheral arterial disease.